reviewed april 2026|next review october 2026|88 physicians psi has verified|9 published studies
Pinealon
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) from the Khavinson bioregulator program at the Saint Petersburg Institute of Bioregulation and Gerontology, studied for neuroprotective effects and pineal gland function modulation, with all 9 published studies originating from a single research group.
Evidence landscape: 9 published studies
9 published items. 0 human studies and 7 animal studies.
- 7 Animal
- 2 Reviews
Not FDA-approved. Not approved by any major Western regulatory authority. Available as a supplement in some markets, primarily Russia and CIS countries. Available as a research compound elsewhere.
9 published studies total. 0 human studies and 7 animal studies. All research originates from a single research group at the Saint Petersburg Institute of Bioregulation and Gerontology. This is the smallest evidence base of any compound in the PSI database.
The Khavinson bioregulator hypothesis proposes that this tripeptide penetrates cell membranes and interacts directly with DNA to regulate gene expression in brain tissue. This mechanism is not widely accepted in Western molecular biology. Cell culture studies report neuroprotective effects through Bcl-2 upregulation and reduced oxidative stress.
PSI Assessment
The evidence base for pinealon comes almost entirely from a single research group at the Saint Petersburg Institute of Bioregulation and Gerontology, and independent Western replication is absent. All 9 published studies originate from this group. No human clinical trials of any kind have been conducted. The Khavinson bioregulator program proposes that this specific three-amino-acid sequence acts as a gene modulator in brain tissue by penetrating cell membranes and interacting directly with DNA. This proposed peptide-DNA interaction mechanism is not widely accepted in Western molecular biology. Cell culture studies from the originating laboratory report neuroprotective effects including reduced oxidative stress and neuronal apoptosis. Whether these effects occur in living organisms at therapeutically meaningful levels is entirely untested.
All 9 published studies from a single research group. Proposed peptide-DNA interaction mechanism not widely accepted in Western molecular biology. No human clinical trials.
The proposed mechanism comes from the Khavinson bioregulator hypothesis: short peptides (2-4 amino acids) can regulate gene expression by binding to specific DNA sequences in gene promoter regions. For pinealon, the proposed targets include genes involved in antioxidant enzyme expression (Bcl-2 upregulation), melatonin biosynthesis (AANAT, HIOMT enzymes), and neuronal apoptosis regulation. In cell culture models, pinealon has been reported to reduce reactive oxygen species (ROS) and lipid peroxidation in neuronal cell lines. Whether a three-amino-acid peptide can survive systemic administration, cross the blood-brain barrier, and produce tissue-specific gene modulation in the pineal gland is not supported by pharmacokinetic evidence from any laboratory.
What the evidence supports
Cell culture studies report neuroprotective effects including reduced oxidative stress and neuronal apoptosis through Bcl-2 upregulation. The Khavinson bioregulator program has produced internally consistent data across the pinealon research series. The tripeptide structure is well-characterized.
What is not yet established
Independent replication by any laboratory outside the Saint Petersburg Institute. Human safety, pharmacokinetics, or efficacy data of any kind. Whether the proposed peptide-DNA interaction mechanism is accurate. Whether pinealon produces any measurable effect on pineal gland function in living organisms.
Research Evidence
The findings below reflect the limited evidence that exists and highlight the critical gaps.
Evidence by condition
Evidence dimensions across pinealon research areas. Neuroprotection has cell culture data from the originating laboratory. Pineal function has animal data from the same group. Aging/longevity is at the earliest theoretical stage. Controlled human data has not been published for any indication.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Neuroprotection | ||||
| Pineal Function | ||||
| Aging/Longevity |
Cell culture studies from the Khavinson laboratory report neuroprotective effects including reduced neuronal apoptosis and oxidative damage through Bcl-2 upregulation and ROS reduction in neuronal cell lines.
These findings are internally consistent within the originating laboratory's publications. No independent laboratory has attempted to replicate them.
All 9 published studies on pinealon originate from the Saint Petersburg Institute of Bioregulation and Gerontology or closely affiliated institutions. No independent Western laboratory has published research on pinealon.
Single-source evidence without independent replication is the most significant limitation of pinealon's evidence base. In science, findings that have not been independently reproduced carry substantially lower confidence regardless of how many papers a single group publishes.
The Khavinson bioregulator program proposes that short peptides (2-4 amino acids) regulate gene expression by penetrating cell membranes and binding directly to DNA promoter regions. This mechanism, if accurate, would represent a novel biological pathway not described in mainstream molecular biology.
The proposed peptide-DNA interaction is the theoretical basis for the entire bioregulator peptide class. It has not been independently validated. Whether a tripeptide can produce tissue-specific effects after systemic administration is not supported by pharmacokinetic evidence.
0 Human|7 Animal|2 Reviews
View all 9 indexed studiesHow Pinealon Works
Pinealon is a synthetic tripeptide, which means it is one of the shortest possible peptides at only three amino acids long (Glu-Asp-Arg). It is designed as a bioregulator that the Khavinson program proposes can specifically target brain cells, particularly in the pineal gland, the small structure in the brain that controls sleep rhythms and melatonin production.
Pinealon is thought to act as a regulatory signal specifically for brain cells, particularly in the pineal gland. The idea is that this tiny protein fragment tells certain brain genes to turn on or off, potentially helping maintain the sleep-wake cycles and melatonin production that the pineal gland controls.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Pinealon (Glu-Asp-Arg) is proposed to act as a peptide bioregulator of brain tissue, specifically the pineal gland and central nervous system neurons. The Khavinson bioregulator hypothesis proposes that short peptides (2-4 amino acids) regulate gene expression by binding to specific DNA sequences in gene promoter regions. In cell culture, pinealon has been reported to increase expression of anti-apoptotic factors (Bcl-2), reduce markers of oxidative stress (ROS, lipid peroxidation), and potentially modulate melatonin biosynthesis enzymes (AANAT, HIOMT). These findings remain entirely unvalidated outside Russian research institutions.
What is Pinealon being studied for?
Researchers are studying Pinealon across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Pinealon overall. This means a compound can have human studies for one condition but only animal data for another.
Neuroprotection
·Animal StudiesCell culture and animal studies from the Khavinson group suggest pinealon protects neurons from oxidative stress. No independent replication. No human data.
Limitations: All data from a single research group. No independent replication. No human neuroprotection data of any kind.
Pineal Function
·Animal StudiesThe name derives from its proposed targeting of pineal tissue. Limited evidence suggests it may influence melatonin synthesis in animal models.
Limitations: No human data. The tissue-specificity claim for a systemically administered tripeptide is not supported by pharmacokinetic evidence.
Aging/Longevity
·PreclinicalPart of Khavinson's bioregulator longevity program. Some animal lifespan data exists within the originating laboratory.
Limitations: No controlled human aging studies. The bioregulator longevity concept itself lacks independent validation.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Not approved by any major Western regulatory authority. Not recognized as a therapeutic agent by any Western regulatory body.
Availability: Available as a supplement in some markets, primarily Russia and CIS countries. Available as a research compound from peptide suppliers in other markets.
Class context: No human safety data of any kind. As a tripeptide (three amino acids), it is structurally simple and unlikely to produce acute toxicity. The total body of evidence is too small (9 studies) for any meaningful safety conclusions.
Pinealon has no human safety data. As a tripeptide (three amino acids), it is structurally simple and unlikely to produce acute toxicity based on its amino acid composition. No adverse effects have been reported in the limited animal studies. The pharmacokinetics (absorption, distribution, half-life) in humans are entirely unknown.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Pinealon discussion.
Comparison and Related Research
Pinealon is most often compared with other Khavinson bioregulator peptides and neuroprotective compounds. The comparisons below outline how each differs.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Demonstrated that pinealon (Glu-Asp-Arg) exerts neuroprotective effects in cell culture by suppressing reactive oxygen species and promoting cell proliferation. The tripeptide increased viability of cortical neurons exposed to oxidative stress, suggesting a mechanism of action through antioxidant and pro-survival signaling pathways.Khavinson V et al., 2011 in Rejuvenation Res. View on PubMed
- 2.Investigated the effects of short peptide bioregulators including pinealon on serotonin expression in brain cortex cell cultures. Found that pinealon stimulated serotonin synthesis in cortical neurons, providing evidence for a specific neurochemical mechanism through which this tripeptide may influence central nervous system function.Khavinson VKh et al., 2014 in Bull Exp Biol Med. View on PubMed
- 3.Examined the effects of bioregulatory tripeptides including pinealon on skin cell cultures derived from young and aged rats. The study found age-dependent responses: peptide bioregulators showed differential effects on cell proliferation and viability depending on donor age, suggesting that these peptides may interact with age-related changes in cellular signaling.Voicekhovskaya MA et al., 2012 in Bull Exp Biol Med. View on PubMed
- 4.Studied the effects of pinealon and related short peptides on signaling molecule expression in organotypic pineal gland cell cultures. Demonstrated that pinealon modulates the expression of neuroendocrine signaling molecules in pineal tissue, supporting the hypothesis that this tripeptide acts as a targeted regulator of pineal gland function.Khavinson VKh et al., 2011 in Bull Exp Biol Med. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.